Article ; Online: Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.
2019 Volume 33, Issue 8, Page(s) 1996–2005
Abstract: We conducted a large international nested case-control study including 1881 patients with Philadelphia-negative myeloproliferative neoplasms (MPN). Cases (n = 647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological ... ...
Abstract | We conducted a large international nested case-control study including 1881 patients with Philadelphia-negative myeloproliferative neoplasms (MPN). Cases (n = 647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological second cancer, and melanoma) and controls (n = 1234) were patients without SC, matched with cases for sex, age at MPN diagnosis, date of MPN diagnosis, and MPN disease duration. The aim was to evaluate the risk of SC after exposure to cytoreductive drugs. Patients exposed to hydroxyurea (HU) (median: 3 years) had a risk of SC similar to unexposed patients (OR = 1.06, 95% CI 0.82-1.38). In contrast, in cancer-specific stratified multivariable analysis, HU had two-fold higher risk of non-melanoma (NM) skin cancer (OR = 2.28, 95% CI 1.15-4.51). A significantly higher risk of NM-skin cancer was also documented for pipobroman (OR = 3.74, 95% CI 1.00-14.01), ruxolitinib (OR = 3.87, 95% CI 1.18-12.75), and for drug combination (OR = 3.47, 95% CI 1.55-7.75). These three drugs did not show excess risk of carcinoma and hematological second cancer compared with unexposed patients. Exposure to interferon, busulfan, and anagrelide did not increase the risk. In summary, while it is reassuring that no excess of carcinoma was documented, a careful dermatologic active surveillance before and during the course of treatments is recommended. |
---|---|
MeSH term(s) | Antineoplastic Agents/adverse effects ; Case-Control Studies ; Humans ; Hydroxyurea/adverse effects ; Neoplasms, Second Primary/chemically induced ; Philadelphia Chromosome ; Pipobroman/adverse effects ; Polycythemia Vera/drug therapy ; Polycythemia Vera/genetics ; Primary Myelofibrosis/drug therapy ; Pyrazoles/adverse effects ; Thrombocythemia, Essential/drug therapy ; Thrombocythemia, Essential/genetics |
Chemical Substances | Antineoplastic Agents ; Pyrazoles ; Pipobroman (6Q99RDT97R) ; ruxolitinib (82S8X8XX8H) ; Hydroxyurea (X6Q56QN5QC) |
Language | English |
Publishing date | 2019-05-29 |
Publishing country | England |
Document type | Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't |
ZDB-ID | 807030-1 |
ISSN | 1476-5551 ; 0887-6924 |
ISSN (online) | 1476-5551 |
ISSN | 0887-6924 |
DOI | 10.1038/s41375-019-0487-8 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 2295: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.